ES254048A1 - Method of prolonging release of drug from a precompressed solid carrier - Google Patents

Method of prolonging release of drug from a precompressed solid carrier

Info

Publication number
ES254048A1
ES254048A1 ES0254048A ES254048A ES254048A1 ES 254048 A1 ES254048 A1 ES 254048A1 ES 0254048 A ES0254048 A ES 0254048A ES 254048 A ES254048 A ES 254048A ES 254048 A1 ES254048 A1 ES 254048A1
Authority
ES
Spain
Prior art keywords
plastic
specified
drug
salts
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES0254048A
Other languages
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of ES254048A1 publication Critical patent/ES254048A1/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

A plastic composition comprising a foraminous matrix of a plastic having particles of a solid drug dispersed in the interstices thereof is produced by coalescing individual particles of a plastic in a compressed mixture of a drug and a plastic which is non-toxic and inert to gastro-intestinal fluids by exposing said mixture to the vapour of an organic solvent for the plastic preferably in a confined space. The exposure may be carried out at room temperature and atmospheric pressure for a period of 3 to 24 hrs. or at higher temperatures and reduced pressures. Specified plastics are polyethylene, polymethyl methacrylate, copolymers of methyl methacrylate and alkyl acrylates, e.g. methyl acrylate, polyvinyl acetate and polyhexamethylene adipamide. Specified organic solvents are methylene chloride, ethyl acetate, ethylene dichloride, toluene and acetone. Specified drugs are methamphetamine salts, e.g. the hydrochloride, hexocyclium methyl sulphate, para-amino benzoic acid and its sodium salt, ephedrine, mannitol hexanitrate, amphetamine, erythromycin salts, penicillin salts, pentobarbital, phenobarbital, phenobarbital sodium, atropine, belladonna, theophylline, sex hormones, hydantoins, trimethadione, water soluble vitamins such as B and C, nicotinic acid, benzazoline or toluidine blue O. The mixture of drug and plastic used in the above method may be prepared by any of the processes described in Specification 833,458. In order to increase the water permeability of the composition water-soluble excipients such as dextrose acacici, sodium chloride, sucrose, polyethylene glycols, sorbitol, urea, polyvinyl pyrrolidone, inositol, lactose, mannitol, "Methocel" (Registered Trade Mark), calcium chloride and pectin may be added. Other adjuvants specified are talc and magnesium stearate.ALSO:A prolonged release medicament comprising a foraminous matrix of a plastic having particles of a solid drug dispersed in the interstices thereof, is produced by coalescing individual particles of plastic in a compressed mixture of a drug and a plastic which is non-toxic and inert to gastro-intestinal fluids by exposing said mixture to the vapour of an organic solvent for the plastic preferably in a confined space. The exposure may be carried out at room temperature and atmospheric pressure for a period of 3 to 24 hours or at higher temperatures and reduced pressures. Specified organic solvents are methylene chloride, ethyl acetate, ethylene dichloride, toluene or acetone. Specified drugs are methamphetamine salts, e.g. the hydrochloride, hexocyclium methyl sulphate, para-aminobenzoic acid and its sodium salt, ephedrine, mannitol hexanitrate, amphetamine, erythromycin salts, penicillin salts, pentobarbital, phenobarbital sodium, atropene, belladona, theophylline, sex hormones, hydantoins, trimethadione, water-soluble vitamins such as B and C, nicotinic acid, benzazoline or toluidine blue O. Specified plastics are polyethylene, polymethylmethacrylate, copolymers of methyl-methacrylate and alkyl acrylates e.g. methyl acrylate, polyvinyl acetate or polyhexamethylene adipamide. The mixture of drug and plastic used in the above method may be prepared by any of the processes described in Specification 833,458. In order to increase the water permeability of the composition water-soluble excipients such as dextrose, acacia, sodium chloride, sucrose, polyethylene glycols, sorbitol, urea, polyvinylpyrrolidone, inositol, lactose, mannitol, "Methocel" (Registered Trade Mark), calcium chloride and pectin may be added. Other adjuvants specified are talc and magnesium stearate.
ES0254048A 1958-12-19 1959-12-09 Method of prolonging release of drug from a precompressed solid carrier Expired ES254048A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US781433A US3087860A (en) 1958-12-19 1958-12-19 Method of prolonging release of drug from a precompressed solid carrier

Publications (1)

Publication Number Publication Date
ES254048A1 true ES254048A1 (en) 1960-02-16

Family

ID=25122720

Family Applications (1)

Application Number Title Priority Date Filing Date
ES0254048A Expired ES254048A1 (en) 1958-12-19 1959-12-09 Method of prolonging release of drug from a precompressed solid carrier

Country Status (4)

Country Link
US (1) US3087860A (en)
BE (1) BE585579A (en)
ES (1) ES254048A1 (en)
GB (1) GB908016A (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138544A (en) * 1961-05-03 1964-06-23 British Drug Houses Canada Ltd Microbial sensitivity testing device
US3198700A (en) * 1961-05-29 1965-08-03 Blessings Inc Sedative tablet and method for producing the same
NL297357A (en) * 1962-08-31
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3325365A (en) * 1963-04-02 1967-06-13 Ciba Geigy Corp Enteric composition for tablet compression coating
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3453360A (en) * 1966-04-27 1969-07-01 Abbott Lab Universally useful stock material for manufacturing plastic dosage units by compression tableting processes
IE32806B1 (en) * 1968-05-21 1973-12-12 American Home Prod Sustained release drug composition
DE2239206A1 (en) * 1971-08-12 1973-03-15 Hydrophilics Int Inc COPOLYMER
US3995632A (en) * 1973-05-04 1976-12-07 Alza Corporation Osmotic dispenser
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4851231A (en) * 1982-12-13 1989-07-25 Alza Corporation System for delivering drug in selected environment of use
DE3314003A1 (en) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim DIVISIBLE TABLET WITH DELAYED ACTIVE SUBSTANCE RELEASE AND METHOD FOR THE PRODUCTION THEREOF
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
DE3505433A1 (en) * 1985-02-16 1986-08-21 Basf Ag, 6700 Ludwigshafen DIRECT TABLETING AIDS
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
DE3827214A1 (en) * 1988-08-11 1990-02-15 Roehm Gmbh RETARDED MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
US5153002A (en) * 1991-03-04 1992-10-06 University Of Montreal Biocompatible gradient controlled release implant
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
DE19732903A1 (en) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
DE10247037A1 (en) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Solid, rapid release dosage form, especially for sparingly soluble drugs, obtained by forming and cooling softened, shapable mixture of crosslinked non-thermoplastic carrier, adjuvant and active agent
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US7225024B2 (en) * 2003-09-30 2007-05-29 Cardiac Pacemakers, Inc. Sensors having protective eluting coating and method therefor
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US20090062909A1 (en) * 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
CA2615452C (en) 2005-07-15 2015-03-31 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
CA2616416A1 (en) * 2005-09-09 2007-05-03 Labopharm, Inc. Trazodone composition for once a day adminisitiation
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
WO2008042909A2 (en) 2006-10-02 2008-04-10 Micell Technologies Inc. Surgical sutures having increased strength
CA2667228C (en) * 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
CA2684482C (en) * 2007-04-17 2014-08-12 Micell Technologies, Inc. Stents having biodegradable layers
AU2008256684B2 (en) * 2007-05-25 2012-06-14 Micell Technologies, Inc. Polymer films for medical device coating
WO2009051780A1 (en) * 2007-10-19 2009-04-23 Micell Technologies, Inc. Drug coated stents
EP2271294B1 (en) 2008-04-17 2018-03-28 Micell Technologies, Inc. Stents having bioabsorbable layers
JP2011528275A (en) * 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． Drug delivery medical device
WO2010040021A1 (en) * 2008-10-03 2010-04-08 Salix Pharmaceuticals, Ltd. Compositions and methods for the treatment of bowel diseases with granulated mesalamine
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20100239635A1 (en) * 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
CA2756307C (en) * 2009-03-23 2017-08-08 Micell Technologies, Inc. Peripheral stents having layers and reinforcement fibers
WO2010111238A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Improved biodegradable polymers
CN102481195B (en) * 2009-04-01 2015-03-25 米歇尔技术公司 Drug delivery medical device
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc Drug delivery medical device
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
WO2012034079A2 (en) 2010-09-09 2012-03-15 Micell Technologies, Inc. Macrolide dosage forms
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
KR20150143476A (en) 2013-03-12 2015-12-23 미셀 테크놀로지즈, 인코포레이티드 Bioabsorbable biomedical implants
KR102079613B1 (en) 2013-05-15 2020-02-20 미셀 테크놀로지즈, 인코포레이티드 Bioabsorbable biomedical implants

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA548310A (en) * 1957-11-05 M. O. Honey Eric Diaphragms for use in ion exchange processes
USRE24090E (en) * 1955-11-15 Impregnated salt tablet
US312041A (en) * 1885-02-10 Process of making pills
NL44885C (en) * 1935-11-09
US2385920A (en) * 1941-12-19 1945-10-02 Pittsburgh Plate Glass Co Plasticization of plastics
US2478182A (en) * 1945-01-16 1949-08-09 William V Consolazio Sodium chloride tablet
GB665073A (en) * 1948-11-10 1952-01-16 Jacques Loewe Res Foundation I Process of preparing acid-sensitive drugs for oral administration and the product soproduced
US2955982A (en) * 1951-01-22 1960-10-11 Parmelee Pharmaceutical Compan Continuous process for internally reinforcing salt tablets
US2707201A (en) * 1951-05-05 1955-04-26 Richardson Co Porous storage battery separator and method of making
US2719093A (en) * 1952-06-03 1955-09-27 William H Voris Methods of applying plastic coatings
BE538663A (en) * 1954-06-25
US2894289A (en) * 1956-03-01 1959-07-14 Dow Chemical Co Method of making permeselective membranes
NL112156C (en) * 1956-08-07
US2877159A (en) * 1957-04-26 1959-03-10 Ciba Pharm Prod Inc Method for preparing tablet granulations
US2928771A (en) * 1957-07-22 1960-03-15 Strong Cobb And Company Inc Production of orally administrable controlled release medicaments
US2928769A (en) * 1957-07-22 1960-03-15 Strong Cobb And Company Inc Production of controlled release medicaments

Also Published As

Publication number Publication date
US3087860A (en) 1963-04-30
GB908016A (en) 1962-10-10
BE585579A (en) 1960-04-01

Similar Documents

Publication Publication Date Title
ES254048A1 (en) Method of prolonging release of drug from a precompressed solid carrier
KR840005016A (en) Method for preparing sustained release tablet
CA2041774A1 (en) Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
LU88343I2 (en) Terbinafine in all forms including its seis such as hydrochloride
YU71894A (en) NEW PHARMACEUTICALS PREPARATION WITH DIFFUSION-OSMOTIC CONTROL OF LIBERATION AND THE PROCEDURE
NO881732L (en) IBUPROFEN-RELEASING RELEASE MATRIX AND PROCEDURE FOR PREPARING THEREOF.
KR890001526A (en) Oral sustained release acetaminophen formulations and preparation method thereof
KR930701983A (en) Release-Resistant Verapamil Tablets
CO5070679A1 (en) PHARMACEUTICAL TABLET OF ENTERIC COATING AND ELABORATION METHOD
CA2016039A1 (en) Extended release pharmaceutical formulations
DE3373277D1 (en) Process for preparing insoluble, only slightly expandable polymers of basic vinyl-heterocyclic compounds, and their use
KR970702028A (en) Sustained-Release Matrix Pellets and Method for Preparing Them
NO870558D0 (en) PROCEDURE FOR THE PREPARATION OF A SLOW RELEASE PHARMACEUTICAL PREPARATION.
UA27707C2 (en) Prolonged release preparation, polymer base used in prolonged release pharmaceutic preparations and process for preparation thereof
YU46569B (en) PROCEDURE FOR WITHDRAWAL OF TABLETS OR BOLUSES FOR THE CONTROLLED RELEASE OF ONE OR MORE ACTIVE SUBSTANCES
MY109496A (en) Novel formulations of crop protection agents
ATE81450T1 (en) RELEASED RELEASE PHARMACEUTICAL FORM AND PROCESS FOR PRODUCTION.
PE20001454A1 (en) PROCEDURE FOR THE PREPARATION OF A COMPOSITION OF ORAL ADMINISTRATION AND DELAYED RELEASE OF TRAMADOL
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
CS261791A3 (en) Process for preparing preparations in the form of tablets or coated tablets containing light, heat and moisture sensitive active component having a monoclinic crystal structure
PT744947E (en) METRONIDAZOLE COMPOSITIONS WITH MODIFIED LIBERTACAO AND METHODS FOR MAKING AND USING THEM
GB1218978A (en) Pharmaceutical compositions
US6806334B2 (en) Proliferous copolymer of vinyl pyrrolidone and vinyl acetate
ATE72118T1 (en) PHARMACEUTICAL COMPOSITION AND PROCESS FOR PRODUCTION.
ES2062804T3 (en) MEDICINE COATED WITH GELATIN AND PROCEDURE TO MANUFACTURE THE SAME.